MBX Biosciences (MBX) Free Cash Flow (2023 - 2026)

MBX Biosciences has reported Free Cash Flow over the past 4 years, most recently at -$20.6 million for Q1 2026.

  • Quarterly results put Free Cash Flow at -$20.6 million for Q1 2026, up 10.94% from a year ago — trailing twelve months through Mar 2026 was -$79.3 million (down 16.7% YoY), and the annual figure for FY2025 was -$81.9 million, down 47.38%.
  • Free Cash Flow reached -$20.6 million in Q1 2026 per MBX's latest filing, down from -$19.1 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$10.7 million in Q1 2024 and bottomed at -$23.2 million in Q1 2025.
  • Median Free Cash Flow over the past 4 years was -$17.3 million (2024), compared with a mean of -$16.9 million.
  • The largest annual shift saw Free Cash Flow crashed 115.75% in 2025 before it grew 10.94% in 2026.
  • Over 4 years, Free Cash Flow stood at -$11.2 million in 2023, then plummeted by 51.33% to -$16.9 million in 2024, then dropped by 13.02% to -$19.1 million in 2025, then fell by 8.12% to -$20.6 million in 2026.
  • Business Quant data shows Free Cash Flow for MBX at -$20.6 million in Q1 2026, -$19.1 million in Q4 2025, and -$21.9 million in Q3 2025.